Spontaneous Pneumopericard in transdiaphragmal Gastric Ulcer Perforation Based on Post-Transplant Lymphoproliferative Disease (PTLD) of the Gastric Wall

被引：0
|
作者：
Feldhaus, Felix [1 ,2 ,3 ,4 ]
Winter, Axel [2 ,3 ,5 ,6 ]
Rau, Beate [2 ,3 ,5 ,6 ]
Baur, Alexander [1 ,2 ,3 ,4 ]
机构：
[1] Charite Univ Med Berlin, Dept Radiol, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Berlin Inst Hlth, Inst Radiol, Berlin, Germany
[5] Charite Univ Med Berlin, Dept Gen Visceral Vasc & Thorac Surg, Berlin, Germany
[6] Berlin Inst Hlth, Berlin, Germany
来源：
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN | 2019年 / 191卷 / 02期
关键词：
D O I：
10.1055/a-0647-2054
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
[No abstract available]
引用
收藏
页码：137 / 138
页数：2
相关论文
共 50 条
  • [21] Effective high dose chemotherapy for refractory post-transplant lymphoproliferative disease (PTLD) in children.
    Lee, MJ
    Choi, BH
    Kim, KM
    Park, YS
    Huh, J
    Ghim, TT
    BLOOD, 2003, 102 (11) : 459B - 459B
  • [22] Post-transplant Lymphoproliferative Disease Presenting as a Chronic Cough and Necrotic Palatal Ulcer
    Zaveri, A.
    Mishra, P. E.
    Taylor, J. B.
    Gaietto, K. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [23] Multiple drugsHaemophagocytic lymphohistiocytosis (HLH) and lymphoproliferative disease resembling post-transplant lymphoproliferative disease (PTLD) secondary to EBV infection: case report
    Reactions Weekly, 2017, 1653 (1) : 223 - 223
  • [24] Anti-CD20 monoclonal antibody (rituximab) for post-transplant lymphoproliferative disease treatment (PTLD).
    Roithmann, S
    Bonamigo, JL
    Neumann, J
    Fogliatto, L
    Gaiger, AM
    Garcia, VD
    BLOOD, 2000, 96 (11) : 246B - 246B
  • [25] First line treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease (PTLD).
    Gonzalez-Barca, E
    Domingo-Domenech, E
    Gomez-Codina, J
    Capote, F
    Gallur, L
    Oriol, A
    Muñoz, A
    Flores, E
    de Sevilla, AF
    BLOOD, 2003, 102 (11) : 306B - 306B
  • [26] Pharmacological determinants of post-transplant lymphoproliferative disease (PTLD): feasibility of a large case-control study
    Stojanova, J.
    Caillard, S.
    Rousseau, A.
    Roussel, H.
    Rerolle, J.
    Essig, M.
    Marquet, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 65 - 66
  • [27] Solitary intraventricular Hodgkin lymphoma post-transplant lymphoproliferative disease (HL-PTLD): Case report
    Azriel, Amit
    Towner, James E.
    Gaillard, Frank
    Box, Georgia
    Rogers, TeWhiti
    Morokoff, Andrew
    JOURNAL OF CLINICAL NEUROSCIENCE, 2019, 69 : 269 - 272
  • [28] Hydroxyurea (HU) Therapy for Patients With Post-Transplant Lymphoproliferative Disease (PTLD): Treatment and Prevention of New Episodes
    Pereira, P.
    Vince, C.
    Azambuja, A.
    Brumatti, M.
    Cristofani, L.
    Halley, N.
    Pereira, A.
    Zamperlini-Netto, G.
    Guedes, G.
    Odone-Filho, V.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S314 - S315
  • [29] Children are 6 times more likely than adults to develop post-transplant lymphoproliferative disease (PTLD)
    Ford, James
    Sanmann, Jennifer
    Erickson, Kelly
    Bast, Martin
    Grant, Wendy
    Shostrom, Valerie
    Langnas, Alan
    Greiner, Timothy
    Coccia, Peter
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 54 - 54
  • [30] First-line treatment with rituximab improves survival of patients with post-transplant lymphoproliferative disease (PTLD).
    Gonzalez-Barca, E
    Domingo-Domenech, E
    Gomez-Codina, J
    Capote, F
    Flores, E
    Briones, J
    Salar, A
    Panizo, C
    Montalban, C
    Ribera, JM
    Caballero, D
    Muñoz, A
    Gallur, L
    Canales, MA
    Fernandez, P
    Encuentra, M
    de Sevilla, AF
    BLOOD, 2004, 104 (11) : 394A - 394A
12345